Habot-Wilner Zohar, Sorkin Nir, Goldenberg Dafna, Loewenstein Anat, Goldstein Michaella
Department of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ophthalmologica. 2014;232(2):77-82. doi: 10.1159/000362178. Epub 2014 Jul 10.
To report the long-term outcome of an intravitreal dexamethasone drug delivery system (DEX-DDS) injection for noninfectious uveitic macular edema.
This was a retrospective study of 8 eyes (7 patients).
The mean follow-up time was 17.3 months. Macular edema resolved in all eyes at 3.9 weeks (range 1-6.9) postinjection. The central point thickness improved from 612 ± 143 to 250 ± 55 µm (p < 0.05). The mean best corrected visual acuity improved by 0.25 logMAR (p < 0.05) at 3.9 weeks (range 1-6.9) postinjection. In 5 eyes, macular edema did not recur after a mean follow-up of 14.5 months. In 3 eyes, macular edema relapsed after 4.7 months (range 3.6-6.3) and resolved again following further injections. Two eyes developed intraocular pressure elevation, which was well controlled with topical treatment.
Intravitreal DEX-DDS injections resulted in resolution of macular edema and visual acuity improvement. Some eyes required repeated injections, but most eyes achieved long-term resolution. No significant complications were noticed.
报告玻璃体内注射地塞米松药物递送系统（DEX-DDS）治疗非感染性葡萄膜炎性黄斑水肿的长期疗效。
这是一项对8只眼（7例患者）的回顾性研究。
平均随访时间为17.3个月。注射后3.9周（范围1 - 6.9周）时，所有患眼黄斑水肿均消退。中心凹厚度从612±143μm改善至250±55μm（p<0.05）。注射后3.9周（范围1 - 6.9周）时，平均最佳矫正视力提高了0.25 logMAR（p<0.05）。5只眼中，平均随访14.5个月后黄斑水肿未复发。3只眼中，黄斑水肿在4.7个月（范围3.6 - 6.3个月）后复发，再次注射后消退。2只眼出现眼压升高，经局部治疗后得到良好控制。
玻璃体内注射DEX-DDS可使黄斑水肿消退，视力提高。部分患眼需要重复注射，但大多数患眼实现了长期消退。未观察到明显并发症。
